Vistagen Therapeutics (VTGN -8.08%), a clinical-stage biopharmaceutical company developing intranasal therapies for neuropsychiatric and women's health conditions, released its fiscal 2026 first quarter earnings on August 7, 2025. The company's top-line results largely matched expectations: earnings per share (EPS) (GAAP) came in at $(0.47) in Q1 FY2026, directly in line with consensus estimates, while reported revenue of$0.24 million (GAAP) in Q1 FY2026 surpassed the estimate of $0.0 million. R&D spending ...